Immunome (IMNM) Stock Price
Immunome Price
Over the last 3 years Immunome grew revenue by 1.6% annually, reaching 6.94 M USD. For Immunome, the net margin of -3,060.0% is down versus -556.8% a few years ago. The consensus 12-month price target for Immunome is 35.50 USD, about 106.4% above where the stock trades today. Of 20 analysts, 19 rate the stock a buy — an overall Buy consensus.
Immunome stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Immunome business model & stock analysis
Frequently asked questions about Immunome
The business model of Immunome Inc is focused on developing targeted antibody therapies for the treatment of cancer and other diseases. The company utilizes its proprietary discovery engine, known as IMM-01, to identify novel disease-targeting antigens and generate highly specific monoclonal antibodies. These therapeutic antibodies have the potential to selectively bind to disease-related targets, thereby stimulating an immune response against cancer cells or other disease-causing agents. Through its research and development efforts, Immunome aims to advance its pipeline of antibody candidates and potentially revolutionize the treatment options available for patients.
Immunome Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Immunome Inc in the market are other companies operating in the biotechnology and pharmaceutical industries. These competitors may include companies such as Moderna Inc, BioNTech SE, Pfizer Inc, Johnson & Johnson, and Novavax Inc. Immunome Inc faces competition in the development and commercialization of novel immunotherapies and vaccines. It continuously strives to differentiate itself through its innovative pipeline, cutting-edge technology, and strong research capabilities.
Immunome Inc is a biotechnology company focused on discovering and developing novel immunotherapies for treating cancers and infectious diseases. Founded in [year], Immunome has already achieved significant milestones in its journey. The company's team of scientists and researchers utilize cutting-edge technologies to identify and isolate highly effective antibodies that can specifically target disease-causing agents. Immunome's groundbreaking work has garnered recognition in the scientific community and has attracted collaborations with leading pharmaceutical companies. With a vision to revolutionize the field of immunotherapy, Immunome Inc continues to advance its pipeline of potential treatments, offering hope for patients worldwide.
Immunome Inc. has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in October 2020, raising $26 million. In January 2021, Immunome entered into a collaboration agreement with AbCellera to discover and develop antibodies for infectious diseases. This collaboration aims to leverage Immunome's proprietary discovery engine, IMM-BCP, to select and optimize therapeutic candidates. In addition, Immunome has received funding from various sources, including the National Institutes of Health (NIH), to support the development of its pipeline and advance its immunotherapy programs. These milestones demonstrate Immunome Inc.'s progress and commitment to advancing innovative solutions in the field of immunology.
Immunome Inc is primarily present in the United States.
Immunome Inc represents a strong commitment to innovation, cutting-edge research, and the development of novel immunotherapies. The company's corporate philosophy revolves around harnessing the power of the immune system to target and treat diseases, with a particular focus on cancer and infectious diseases. With a team of highly skilled scientists and industry experts, Immunome Inc is dedicated to discovering and advancing breakthrough therapies that can make a meaningful impact in patients' lives. By combining deep knowledge of the immune system with advanced technologies, Immunome Inc strives to deliver transformative treatments to address unmet medical needs.
Analysts currently set an average price target of 35.25 USD for the Immunome stock (median: 35.50 USD), implying +104.9 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Immunome stock: 19 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Immunome to generate revenue of 333,333.00 USD and earnings per share of -2.92 USD.
Converted at the current exchange rate, the Immunome share trades at 15.38 EUR (17.20 USD).
The Immunome share (IMNM) is listed on 1 stock exchanges, including: NASDAQ (IMNM).
Immunome Inc is an innovative biotechnology company specializing in the development of biopharmaceuticals for the treatment of autoimmune diseases and cancer. The company uses its proprietary platform technologies to identify antibodies that specifically bind to target molecules. These antibodies can then be used as therapeutics or biomarkers for disease diagnosis. The company has two main business areas: 1. Research and development of biopharmaceuticals: The company uses its proprietary sequencing and data analytics platform to identify unique antibodies that selectively target disease targets. Immunome has already developed several antibody candidates that are being tested in clinical trials for the treatment of autoimmune diseases and cancer. 2. Diagnostics: Immunome also offers diagnostic solutions based on its proprietary technologies. The company provides molecular diagnostic tests for identifying pathogens in blood and other bodily fluids. These tests enable faster and more accurate diagnosis of infectious diseases and can help detect and combat outbreaks of infectious diseases early on. Immunome aims to offer its customers high-quality products and solutions based on the latest scientific knowledge and technologies. The company invests heavily in research and development to further improve its technologies and products and to find new applications. Some of Immunome's key products include: 1. IMM-01: A novel antibody candidate targeting a target molecule that is overexpressed in autoimmune diseases such as rheumatoid arthritis and lupus. IMM-01 is currently in clinical trials and shows promising results in improving symptoms of autoimmune diseases. 2. IMM-101: An antibody candidate targeting a target molecule expressed in certain types of cancer such as pancreatic cancer and breast cancer. IMM-101 is currently being tested in clinical trials and could be a promising new therapy for cancer patients. 3. Molecular diagnostic tests: Immunome offers a range of molecular diagnostic tests, including tests for identifying bacteria and viruses that cause infectious diseases such as Lyme borreliosis and respiratory infections. Overall, Immunome has a promising business model based on its proprietary technology platform and its focus on developing a new generation of biopharmaceuticals and diagnostic solutions. The company has already developed promising products and is on a strong growth trajectory. By continuously investing in research and development and expanding its product line, Immunome will continue to play a leading role in the biotechnology industry.
The expected revenue of Immunome is 333,333.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Immunome is -254.97 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Immunome is currently -5.89. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Immunome stock.
The price-to-sales ratio (P/S) of Immunome is currently 4,507.32. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Immunome stock.
The Eulerpool Quality Score for Immunome is 2/10.
The ISIN of Immunome is US45257U1088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Immunome is A2QD9D. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Immunome is IMNM. The ticker symbol is used to trade Immunome shares on the stock exchange.
Immunome stock
Immunome Peer Group
Immunome Ticker
Immunome FIGI
All fundamentals and in-depth analysis of Immunome
Our stock analysis for Immunome stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunome. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.